CRNX - Crinetics Pharmaceuticals Inc Stock Price, Fair Value and News

43.26USD+0.29 (+0.67%)Delayed as of 22 Apr 2024, 11:50 am ET

Market Summary

USD43.26+0.29

Delayedas of 22 Apr 2024, 11:50 am

0.67%

CRNX Alerts

6 major insider sales recently.

CRNX Stock Price

View Fullscreen

CRNX RSI Chart

CRNX Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-13.94

Price/Sales (Trailing)

745.22

Price/Free Cashflow

-17.49

CRNX Price/Sales (Trailing)

CRNX Profitability

Return on Equity

-39.79%

Return on Assets

-33.77%

Free Cashflow Yield

-5.72%

CRNX Fundamentals

CRNX Revenue

Revenue (TTM)

4.0M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

CRNX Earnings

Earnings (TTM)

-214.5M

Earnings Growth (Yr)

-33.58%

Earnings Growth (Qtr)

-4.59%

Breaking Down CRNX Revenue

52 Week Range

15.7643.55

(Low)(High)

Last 7 days

-3.6%

Last 30 days

-5.5%

Last 90 days

21.1%

Trailing 12 Months

149.6%

How does CRNX drawdown profile look like?

CRNX Financial Health

Current Ratio

13.07

CRNX Investor Care

Shares Dilution (1Y)

29.10%

Diluted EPS (TTM)

-3.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.3M	4.8M	4.7M	4.0M
2022	2.0M	2.9M	3.8M	4.7M
2021	0	0	0	1.1M
2020	897.0K	897.0K	392.0K	735.0K
2019	2.4M	1.7M	1.7M	1.2M
2018	2.4M	2.3M	2.2M	2.4M
2017	953.0K	1.3M	1.7M	2.0M
2016	0	0	0	589.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Crinetics Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	struthers richard scott	acquired	38,200	1.91	20,000	president & ceo
Apr 15, 2024	pizzuti dana	acquired	242,794	16.89	14,375	chief med and dev officer
Apr 15, 2024	pizzuti dana	sold	-639,256	44.47	-14,375	chief med and dev officer
Apr 04, 2024	struthers richard scott	acquired	380,025	9.28	40,951	president & ceo
Apr 04, 2024	struthers richard scott	sold	-2,013,560	49.17	-40,951	president & ceo
Mar 28, 2024	okey stephanie	sold	-811,650	46.38	-17,500	-
Mar 28, 2024	okey stephanie	acquired	320,075	18.29	17,500	-
Mar 22, 2024	knight jeff e.	sold	-1,433,680	44.3053	-32,359	chief operating officer
Mar 22, 2024	knight jeff e.	acquired	719,400	23.98	30,000	chief operating officer
Mar 20, 2024	fust matthew k	sold	-2,103,520	44.2847	-47,500	-

Which funds bought or sold CRNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Park Place Capital Corp	new	-	843	843	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	2.49	460,699	1,782,850	0.10%
Apr 15, 2024	Legato Capital Management LLC	reduced	-14.64	50,645	462,483	0.06%
Apr 11, 2024	SANDERS MORRIS HARRIS LLC	unchanged	-	208,134	870,666	0.16%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	494	2,060	-%
Apr 05, 2024	GAMMA Investing LLC	added	38.1	1,183	2,715	-%
Mar 27, 2024	NOMURA HOLDINGS INC	sold off	-100	-943,353	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	213	213	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.8	23,292,000	124,617,000	-%
Mar 05, 2024	Fisher Asset Management, LLC	added	719	14,099,500	15,701,300	0.01%

Are Funds Buying or Selling CRNX?

Are funds buying CRNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRNX

No. of Funds

CRNX Alerts

6 major insider sales recently.

Unveiling Crinetics Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	ecor1 capital, llc	5.3%	4,155,375	SC 13G
Mar 01, 2024	perceptive advisors llc	1.9%	1,488,703	SC 13D/A
Feb 14, 2024	braidwell lp	0%	0	SC 13G/A
Feb 14, 2024	driehaus capital management llc	7.54%	5,039,477	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	-	0	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	5.1%	3,416,900	SC 13G/A
Feb 14, 2024	orbimed advisors llc	2.5%	1,667,360	SC 13G/A
Feb 13, 2024	vanguard group inc	5.24%	3,502,452	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G
Feb 08, 2024	wellington management group llp	4.86%	3,245,105	SC 13G/A

Recent SEC filings of Crinetics Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 08, 2024	4	Insider Trading
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	8-K	Current Report
Apr 02, 2024	4	Insider Trading
Mar 28, 2024	144	Notice of Insider Sale Intent
Mar 26, 2024	4	Insider Trading
Mar 22, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Crinetics Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Crinetics Pharmaceuticals Inc News

Latest updates

Crinetics Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-100.0%	-	346,000	988,000	2,679,000	709,000	458,000	439,000	3,131,000	2,087,333	1,043,667	-	-	71,000	321,000	505,000	-	367,000	781,000	548,000	657,000	442,000
Operating Expenses	5.6%	62,658,000	59,323,000	53,983,000	50,657,000	48,265,000	43,912,000	43,484,000	36,958,000	31,966,000	21,791,000	18,451,000	16,929,000	17,853,000	15,535,000	15,734,000	13,345,000	10,411,000	10,212,000	8,618,000	6,340,000	5,968,000
S&GA Expenses	10.3%	17,078,000	15,484,000	13,343,000	12,189,000	11,274,000	11,925,000	10,489,000	8,706,000	7,362,000	4,961,000	4,752,000	4,322,000	3,991,000	3,392,000	3,911,000	3,060,000	3,156,000	2,561,000	1,732,000	1,118,000	1,248,000
R&D Expenses	4.0%	45,580,000	43,839,000	40,640,000	38,468,000	36,991,000	31,987,000	32,995,000	28,252,000	24,604,000	16,830,000	13,699,000	12,607,000	13,862,000	12,143,000	11,823,000	10,285,000	7,255,000	7,651,000	6,886,000	5,222,000	4,720,000
EBITDA Margin	-	-	-	-	-	-	-	-14.95	-8.52	-99.00	-1,026	-126	-55.16	-55.18	-41.51	-15.87	-15.52	-11.26	-	-	-	-
EBT Margin	-	-	-	-	-	-	-	-15.08	-8.59	-99.85	-1,039	-128	-56.21	-56.21	-42.26	-16.40	-15.99	-11.52	-	-	-	-
Net Income	-4.6%	-60,097,000	-57,458,000	-50,979,000	-45,995,000	-44,991,000	-41,925,000	-42,375,000	-34,627,000	-30,794,000	-21,641,000	-18,320,000	-16,491,000	-17,360,000	-14,549,000	-14,430,000	-12,427,000	-9,016,000	-8,495,000	-7,588,000	-5,568,000	-5,464,000
Net Income Margin	-26.6%	-53.46	-42.23	-38.04	-40.91	-34.60	-39.17	-46.65	-59.90	-99.85	-139	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	12.0%	-39,450,000	-44,839,000	-45,972,000	-40,734,000	-35,481,000	-39,161,000	-28,589,000	-13,630,000	-22,917,000	-15,955,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.0%	635	642	293	314	352	385	422	333	351	209	217	164	183	200	217	124	130	143	155	167	171
Current Assets	-0.3%	574	576	285	305	345	378	416	328	345	204	211	158	177	194	211	117	123	135	148	159	167
Cash Equivalents	-61.6%	55.00	143	40.00	41.00	33.00	31.00	62.00	146	201	162	179	106	94.00	118	161	51.00	41.00	67.00	60.00	63.00	45.00
Net PPE	11.4%	11.00	10.00	3.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	2.6%	96.00	94.00	39.00	34.00	36.00	34.00	36.00	30.00	19.00	16.00	15.00	14.00	15.00	13.00	14.00	15.00	13.00	13.00	13.00	14.00	11.00
Current Liabilities	8.6%	44.00	40.00	33.00	26.00	28.00	25.00	26.00	20.00	16.00	12.00	12.00	10.00	10.00	9.00	10.00	11.00	8.00	8.00	8.00	9.00	8.00
Shareholder's Equity	-1.6%	539	548	254	280	316	351	386	303	332	194	201	149	169	187	203	108	117	130	142	152	160
Retained Earnings	-10.1%	-653	-593	-536	-485	-439	-394	-352	-309	-275	-244	-216	-190	-167	-146	-127	-111	-93.80	-79.25	-64.82	-52.40	-43.38
Additional Paid-In Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	204
Shares Outstanding	2.2%	68.00	67.00	55.00	54.00	54.00	54.00	50.00	48.00	38.00	36.00	37.00	33.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,000	-	-	-	1,000	-	-	-	683	-	-	-	506	-	-	-	423	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	6.8%	-38,515	-41,339	-45,735	-40,718	-35,207	-38,479	-27,976	-13,543	-22,899	-25,673	-19,949	-20,067	-15,938	-18,004	-15,855	-12,230	-13,447	-13,607	-12,568	-6,759	-6,009
Share Based Compensation	5.1%	11,617	11,049	10,175	8,096	7,948	7,434	7,131	5,755	5,158	4,555	4,233	3,406	2,971	2,781	2,528	2,147	1,831	1,854	1,581	1,028	847
Cashflow From Investing	54.8%	-87,308	-193,296	31,436	48,755	36,853	6,822	-174,271	-43,384	-101,798	-7,025	19,838	32,502	-8,892	-24,832	17,602	16,339	-12,823	20,448	9,443	24,599	-118,681
Cashflow From Financing	-88.8%	37,925	337,877	12,658	484	115	1,076	118,992	1,780	163,856	15,463	73,303	57.00	97.00	-158	108,150	6,482	17.00	22.00	8.00	20.00	9.00

CRNX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues	$ 4,013	$ 4,737	$ 1,078
Operating expenses:
Research and development	168,527	130,225	84,255
General and administrative	58,094	42,394	24,525
Total operating expenses	226,621	172,619	108,780
Loss from operations	(222,608)	(167,882)	(107,702)
Other income (expense):
Interest income	13,436	4,317	157
Change in fair value of derivative asset	0	600	0
Other income (expense), net	(159)	57	(96)
Total other income, net	13,277	4,974	61
Loss before equity method investment	(209,331)	(162,908)	(107,641)
Loss on equity method investment	(5,198)	(1,010)	0
Net loss	$ (214,529)	$ (163,918)	$ (107,641)
Net loss per share:
Net loss per share - basic	$ (3.69)	$ (3.15)	$ (2.8)
Net loss per share - diluted	$ (3.69)	$ (3.15)	$ (2.8)
Weighted average shares - basic	58,071	51,982	38,436
Weighted average shares - diluted	58,071	51,982	38,436
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities	$ 4,908	$ (3,549)	$ (407)
Comprehensive net loss	$ (209,621)	$ (167,467)	$ (108,048)

CRNX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 54,897	$ 32,672
Investment securities, amortized cost of $502.7 million at December 31, 2023 and $305.7 million at December 31, 2022	503,658	301,753
Prepaid expenses and other current assets	15,598	10,759
Total current assets	574,153	345,184
Property and equipment, net	10,881	3,500
Operating lease right-of-use asset	46,549	1,486
Derivative asset	0	668
Investment in radionetics	470	0
Restricted cash	1,300	1,301
Other assets	2,000	37
Total assets	635,353	352,176
Current liabilities:
Accounts payable and accrued expenses	23,196	15,351
Accrued compensation and related expenses	14,517	9,081
Deferred revenue	2,056	2,240
Operating lease liabilities	4,173	1,051
Total current liabilities	43,942	27,723
Operating lease liability, non-current	47,555	2,024
Deferred revenue, non-current	4,750	6,101
Total liabilities	96,247	35,848
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par; 10,000 shares authorized, no shares issued or outstanding at December 31, 2023 or 2022	0	0
Common stock and paid-in capital, $0.001 par; 200,000 shares authorized, 68,175 shares issued and outstanding at December 31, 2023; 53877 shares issued and outstanding at December 31, 2022	1,191,831	759,432
Accumulated other comprehensive (loss) income	977	(3,931)
Accumulated deficit	(653,702)	(439,173)
Total stockholders’ equity	539,106	316,328
Total liabilities and stockholders’ equity	$ 635,353	$ 352,176

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.

CEO	Dr. R. Scott Struthers Ph.D.
WEBSITE	crinetics.com
INDUSTRY	Biotechnology
EMPLOYEES	210

Crinetics Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Crinetics Pharmaceuticals Inc? What does CRNX stand for in stocks?

CRNX is the stock ticker symbol of Crinetics Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Crinetics Pharmaceuticals Inc (CRNX)?

As of Fri Apr 19 2024, market cap of Crinetics Pharmaceuticals Inc is 2.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRNX stock?

You can check CRNX's fair value in chart for subscribers.

What is the fair value of CRNX stock?

You can check CRNX's fair value in chart for subscribers. The fair value of Crinetics Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Crinetics Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Crinetics Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CRNX is over valued or under valued. Whether Crinetics Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Crinetics Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRNX.

What is Crinetics Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, CRNX's PE ratio (Price to Earnings) is -13.94 and Price to Sales (PS) ratio is 745.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRNX PE ratio will change depending on the future growth rate expectations of investors.